Literature DB >> 9352126

Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis.

G B Gabrielli1, F Capra, M Casaril, S Squarzoni, P Tognella, R Dagradi, E De Maria, R Colombari, R Corrocher, G De Sandre.   

Abstract

Laminin P1 (pepsin-resistant fragment of laminin) and aminoterminal peptide of type III procollagen are measurable in serum and are now considered useful serum markers of fibrogenesis and inflammation in chronic liver diseases. However, very few studies thus far have focused on assessing the diagnostic value of these markers in detecting fibrosis and necro-inflammatory activity in chronically diseased liver. The aim of the present study was therefore to investigate the correlations of laminin and type III procollagen with liver histology and to compare their diagnostic value in detecting the degree of liver fibrosis and necro-inflammatory activity in a homogeneous group of 99 patients suffering from chronic hepatitis C, and lacking other factors which can directly affect the serum levels of the two markers. Both these serum markers were measured by radioimmunoassay, employing commercially available kits. The three main aspects of liver pathology, i.e. portal-periportal activity, lobular activity and fibrosis, were histologically evaluated and semiquantitatively expressed by numerical scores. The results of this study show that laminin and type III procollagen were both positively correlated with the histological scores for portal-periportal activity and with those for fibrosis, whereas no significant correlation was observed between each of the two serum markers and the histological scores for lobular activity. The sensitivity and specificity of laminin and type III procollagen in detecting histological aspects of fibrosis and disease activity in liver, computed at various cut-off levels, showed overlapping trends for the two markers; however, the diagnostic value was in general rather low, whatever the cut-off considered. We therefore conclude that the 'static' measurement of both serum laminin and type III procollagen is of limited value for individual diagnosis of liver damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352126     DOI: 10.1016/s0009-8981(97)00103-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis.

Authors:  Mehmet Horoz; Mehmet Aslan; Fusun F Bolukbas; Cengiz Bolukbas; Yasar Nazligul; Hakim Celik; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  Sevil Uygun Ilikhan; Muammer Bilici; Hatice Sahin; Ayşe Semra Demir Akca; Murat Can; Ibrahim Ilker Oz; Berrak Guven; M Cagatay Buyukuysal; Yucel Ustundag
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 3.  Hepatic fibrosis: are any of the serum markers useful?

Authors:  S Oh; N H Afdhal
Journal:  Curr Gastroenterol Rep       Date:  2001-02

4.  Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters.

Authors:  Lun-Gen Lu; Min-De Zeng; Mo-Bin Wan; Cheng-Zhong Li; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Ai-Ping Cao; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

5.  Molecular serum markers of liver fibrosis.

Authors:  Tianhui Liu; Xiaoming Wang; Morten A Karsdal; Diana J Leeming; Federica Genovese
Journal:  Biomark Insights       Date:  2012-07-23

6.  Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis.

Authors:  Shelley S Selph; Alexander D Ginsburg; Roger Chou
Journal:  Syst Rev       Date:  2014-09-19

7.  Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.

Authors:  Bevin Gangadharan; Manisha Bapat; Jan Rossa; Robin Antrobus; David Chittenden; Bettina Kampa; Eleanor Barnes; Paul Klenerman; Raymond A Dwek; Nicole Zitzmann
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

8.  Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats.

Authors:  Jin-Rong Xia; Nai-Feng Liu; Nai-Xun Zhu
Journal:  Int J Mol Sci       Date:  2008-04-24       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.